Designed around the way
your specialty works.
Cancer disease episode with tumour characterization, staging versions, treatment lines/cycles and response.
Assemble pathology, imaging, biomarkers/genomics, stage, comorbidities, functional status and patient priorities for multidisciplinary review.
Plan systemic therapy with protocol/version, intent, line, cycles, day-level orders, consent and pre-treatment checks.
Coordinate pharmacy verification, infusion administration, radiation/surgical referrals, toxicity and supportive/palliative care.
Maintain response/progression, survivorship and recurrence timeline with registry export and trial eligibility reviewed by clinicians.
Diagnosis coverage and clinical records
Primary malignancy by site/histology; metastatic disease with primary linkage; haematological malignancy; recurrence and treatment complications. Store clinical/pathological stage separately, named staging system/edition and date; biomarkers retain specimen, assay and interpretive provenance.
Measurements that give the record meaning
| Measurement | Units / representation | Clinical context |
|---|---|---|
| Tumour burden | mm; lesion sum | Assessment method, target/non-target status and images |
| Stage/grade | coded category | System, edition and evidence date |
| Performance status | ECOG or chosen score | Assessor and version |
| Weight/BSA | kg; m² | Formula/date and treatment verification |
| Blood counts/organ function | analyte-specific units | Collection relative to treatment cycle |
| Toxicity | graded event | Terminology/version, onset, attribution and resolution |
| Delivered treatment | mg; units; Gy/fractions as applicable | Planned versus actual, cumulative exposure and interruptions |
Equipment and integration plans
- Infusion systems → administration evidence via Pharmacy; pathology/genomic labs → structured report plus original; radiotherapy OIS/TPS → authorized plan/delivery summaries, commonly specialized interfaces.
- DICOM RT objects require specialist handling and physics approval; importing a plan is not permission for EMR-directed radiation delivery.
Connections require an approved interface and testing against the installed manufacturer, model and software. Listed equipment is a candidate integration target.
Explore equipment & roboticsReporting and meaningful outcomes
Time to treatment with starting event defined; cycle delays by reason; toxicity follow-up; response and survival summaries with censoring/follow-up explicitly handled.
Development scope and clinical validation
Initial scope
Disease/stage timeline, MDT, treatment plan, cycle record, toxicities and follow-up.
Advanced scope
Validated prescribing, infusion/OIS/genomics connectors and mCODE-based exchange.
Example acceptance scenarios
- Protocol changes must not retroactively modify prior signed chemotherapy orders.
- A held cycle, dose reduction and adverse event must remain connected; missing required verification cannot be represented as completed treatment.
Research foundations
- HL7 mCODE 4.0.0 STU4 (2025) ↗
- CAP current cancer protocols ↗
- ASHP digital health statements and resources ↗
Research snapshot: 23 September 2026. References inform the proposed design; they do not certify FertPro or establish device compatibility. Diagnosis lists and measurement groups are not treatment protocols.